Biomedical 19F MRI Using Perfluorocarbons

Tuba Güden-Silber1, Sebastian Temme1, Christoph Jacoby1

  • 1Experimental Cardiovascular Imaging, Department of Molecular Cardiology, Heinrich Heine University, Düsseldorf, Germany.

Insights

Fluorine-19 MRI offers specific in vivo imaging of inflammation. This study details protocols for high-resolution fluorine-19 MRI and novel applications for visualizing thrombi using targeted perfluorocarbons.

Area of Science:

  • Medical Imaging
  • Biomedical Engineering
  • Radiology

Background:

  • Fluorine-19 (19F) MRI provides high specificity for in vivo imaging, particularly for inflammatory processes.
  • Combining 19F and 1H MRI allows precise anatomical localization of 19F signals.
  • Perfluorocarbon nanoemulsions are common, biochemically inert contrast agents taken up by macrophages/monocytes in preclinical research.

Purpose of the Study:

  • To describe protocols for obtaining high-resolution, artifact-free 19F MRI.
  • To explore the use of perfluorocarbons with distinct spectral properties for targeted imaging.
  • To demonstrate the visualization of thrombi using 19F MRI.

Main Methods:

  • Development and refinement of imaging protocols for complex 19F MR spectra.
  • Utilizing perfluorocarbons with unique spectral signatures.
  • Employing targeted approaches for specific molecular or cellular visualization.
  • Acquisition of high-resolution 19F and 1H MR images.

Main Results:

  • Protocols established for high-resolution, artifact-free 19F MRI.
  • Demonstrated feasibility of visualizing thrombi using targeted perfluorocarbons.
  • Showcased the potential of spectrally distinct perfluorocarbons for advanced imaging applications.

Conclusions:

  • 19F MRI, when combined with optimized protocols and targeted agents, is a powerful tool for specific in vivo imaging.
  • This technique enables precise anatomical localization and visualization of biological processes like inflammation and thrombosis.
  • Future applications include advanced diagnostics and targeted therapies.